BioLattice Ophthalmics, Inc,
Biotechnology · PHILADELPHIA, PA
BiotechnologySEC Form D
BioLattice Ophthalmics, Inc, filed a Form D with the U.S. Securities and Exchange Commission on March 30, 2026, reporting $575,000 raised toward a $2,500,000 offering.
Incorporated in Delaware and based in PHILADELPHIA, PA, it operates in the Biotechnology sector.
Companies file a Form D within 15 days of the first sale of securities in a private offering under Regulation D — an early, public signal that BioLattice Ophthalmics, Inc, has raised capital from private investors.
Browse more recently funded companies in Biotechnology.
Executives & Directors
- Linda AlunkalExecutive Officer · Director
- Amelia ZellanderExecutive Officer · Director
- Gregory JacksonDirector
Recently funded in Biotechnology
Other companies that recently filed a Form D
$3.2MRaised
Goldenrod Therapeutics, Inc.
$10.0MRaised
Human Biotech, Inc.
$1.0MRaised
Optimeos Life Sciences, Inc.
$2.5MRaised
BioStem Technologies, Inc.
$1.6MRaised